VivaDiag™ SARS-CoV-2/Flu A/Flu B Ag Rapid Test (anterionasal)

Description

VivaDiag™ SARS-CoV-2/Flu A/Flu B Ag Rapid Test (anterionasal).

– Listed by the German Federal Institute for Drugs and Medical Devices (BfArM) –

The VivaDiag™ SARS-CoV-2/Flu A/Flu B Ag Rapid Test is designed for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigen, Influenza A and Influenza B virus antigens in human nasal swab, oropharyngeal swab or nasopharyngeal swab specimens. The test is intended for in vitro diagnostic use only. The VivaDiag™ SARS-CoV-2/Flu A/Flu B Ag Rapid Test is based on immunochromatography technology. Each test device has one line of anti-SARS coronavirus antibody on the detection line (Cov line), one line of anti-influenza A antibody on the detection line (A line), one line of anti-influenza B antibody on the detection line (B line), and one line of anti-mouse IgG antibody on the quality control line (C line). When the extracted sample is added to the sample well, it reacts with the labeled antibody to form a complex. The mixture then migrates through the membrane by capillary action and interacts with the coated anti-SARS coronavirus antibody, anti-influenza A antibody, and anti-influenza B antibody on the detection line.

Features of the test:

• Easy to use – anterionasal.
• Diagnostic sensitivity (SARS-CoV-2): 94.12 percent.
• Diagnostic specificity (SARS-CoV-2): 99.68 percent.
• Storage at room temperature (2-30℃)
• Quick result in only 15 minutes.
• BfArM-listed.
• CE certified.